Application of ginsenoside Rh1 in preparation of drugs for improving glucocorticoid resistance

A technology of glucocorticoids and ginsenosides, applied in the field of medicine, can solve the problems of less research and achieve the effects of improving hormone resistance, reducing patient pain, and improving anti-inflammatory effects

Inactive Publication Date: 2014-07-16
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Ginsenoside Rh1 (20S-ginsenoside Rh1) (see formula 1 for the structural formula) exists in a small amount in ginseng medicinal materials, and there are few studies at present. It mainly has myocardial injury repair, inhibition of tumor cell invasion and metastasis, and anti-allergic effects
The regulation of ginsenoside Rh1 on glucocorticoid receptors, and its research on improving hormone resistance has not been reported in the literature

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ginsenoside Rh1 in preparation of drugs for improving glucocorticoid resistance
  • Application of ginsenoside Rh1 in preparation of drugs for improving glucocorticoid resistance
  • Application of ginsenoside Rh1 in preparation of drugs for improving glucocorticoid resistance

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Example 1 (in vitro study of ginsenoside Rh1 improving hormone resistance and improving the anti-inflammatory effect of dexamethasone)

[0021] (1) Materials and methods

[0022] 1. Cell line: mouse monocyte-macrophage (RAW264.7), purchased from ATCC. Primary mouse hepatocytes were isolated from BALB / C mice. The above cell lines were incubated in DMEM medium containing 10% fetal bovine serum at 37°C with a volume fraction of 5% CO 2 , Routine culture under fully saturated humidity conditions, replace the medium after 48 hours, when the cell growth reaches saturation, digest with 0.25% trypsin + 0.02% EDTA for passage, pass once every 2-3 days, and use logarithmic growth phase cells in the experiment.

[0023] 2. The effect of ginsenoside Rh1 on the inflammatory response induced by TNFα.

[0024] 2 × 10 on a 24-well plate 5 and 1×10 5 RAW264.7 cells were plated, and after the cells adhered to the wall, dexamethasone / ginsenoside Rh1+dexamethasone was added (dexametha...

Embodiment 2

[0036] Example 2 (Therapeutic effect of ginsenoside Rh1 combined with dexamethasone on mouse arthritis caused by Freund's adjuvant)

[0037] (1) Materials and methods

[0038] 1. Experimental animals

[0039] DBA-1 mice, 6-8 weeks old, were provided by the Experimental Animal Center of the Second Military Medical University of the Chinese People's Liberation Army. Raised in separate cages under the condition of no special pathogenic bacteria (SPF), controlled room temperature (23±1°C), photoperiod 12 / 12, free to forage for food and drink water.

[0040] 2. Preparation of main reagents

[0041] Mixture of bovine type Ⅱ collagen and complete Freund's adjuvant: take an equal volume of bovine type Ⅱ collagen and complete Freund's adjuvant, fully mix and emulsify until it is still standing for more than 4 hours without delamination.

[0042] 3. Model preparation and group administration

[0043] Modeling: On the first day of modeling, each mouse was subcutaneously injected with...

Embodiment 3

[0048] Embodiment 3 (preparation of ginsenoside Rh1 tablet)

[0049] Take 150g of ginsenoside Rh, 10g of hydroxypropyl methylcellulose, 50g of microcrystalline cellulose, 5g of croscarmellose sodium, mix well, add an appropriate amount of 60% ethanol to make a soft material, pass through a 24-mesh sieve to granulate, Dry at 50°C for 2 hours, pass the dried granules through a 30-mesh sieve for granulation, add 2.5g of magnesium stearate, mix well, and press into 1000 tablets respectively.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses a new medical use of ginsenoside Rh1, and specifically relates to an application of ginsenoside Rh1 in preparation of drugs for improving glucocorticoid resistance. According to the present invention, in vitro and in vivo study results show that: with the ginsenoside Rh1, hormone resistance caused by long term and high dose use of dexamethasone can be significantly improved so as to improve the anti-inflammatory effect of dexamethasone, the action is related to up-regulation of the glucocorticoid receptor, and blood sugar increase can not be caused, such that the application prospects for preparation of the drugs for improving glucocorticoid resistance are provided.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a new medicine application of ginsenoside Rh1. Background technique [0002] Glucocorticoids are widely used in the treatment of various inflammatory and immune-related diseases, such as asthma, rheumatoid arthritis and some autoimmune diseases, but some patients are not sensitive to treatment, even when using high-dose corticosteroids. Shown as hyposensitivity, or insensitivity. Patients with other inflammatory diseases, such as chronic obstructive pulmonary disease, interstitial pneumonia, acute respiratory distress, and cystic fibrosis of the pancreas, are mostly hormone resistant. Since such chronic inflammatory diseases are very common in clinical practice, and the incidence rate is still increasing year by year, if patients show low sensitivity or even resistance to hormone therapy, it will be difficult to obtain effective treatment, and the cost of medical treatment will...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61P3/10A61P29/00A61P19/02
Inventor 杜娟凌昌全李俊
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap